Stanford scientists have developed a method to selectively expand CAR-T cells by co-delivering IL9R with CAR genes using a novel platform that enables rapid CAR-T cell engineering through targeted lentiviral delivery.
Stanford researchers have developed a novel mutant IL-9 receptor (IL9R) that significantly enhances the in vivo engraftment, expansion, and anti-tumor activity of adoptively transferred T cells.
Researchers at Stanford have developed a novel T cell engineering platform that leverages constitutively active interleukin-9 receptor (IL-9R) signaling to improve the efficacy and scalability of immunotherapies for solid tumors.